Cytocare Technologies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 06-07-2024
- Paid Up Capital ₹ 0.10 M
as on 06-07-2024
- Company Age 11 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.26 M
as on 06-07-2024
- Revenue 75.29%
(FY 2023)
- Profit 175.17%
(FY 2023)
- Ebitda 159.38%
(FY 2023)
- Net Worth 116.79%
(FY 2023)
- Total Assets 155.37%
(FY 2023)
About Cytocare Technologies
The Company is engaged in the Chemicals And Resources Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.26 M.
Nedun Murugaiyan and Nedunchezhian Vijayalakshmi serve as directors at the Company.
- CIN/LLPIN
U72200TG2012PTC083748
- Company No.
083748
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Oct 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Cytocare Technologies Private Limited offer?
Cytocare Technologies Private Limited offers a wide range of products and services, including Medical Consultants & Clinics, Medical Consultancy Services, Laboratory & Lab Equipment, Laboratory Mixers.
Who are the key members and board of directors at Cytocare Technologies?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nedun Murugaiyan  | Director | 13-Jan-2020 | Current |
| Nedunchezhian Vijayalakshmi | Director | 08-Feb-2022 | Current |
Financial Performance and Corporate Structure Insights of Cytocare Technologies.
Cytocare Technologies Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 75.29% increase. The company also saw a substantial improvement in profitability, with a 175.17% increase in profit. The company's net worth Soared by an impressive increase of 116.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cytocare Technologies?
In 2023, Cytocare Technologies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Dec 2023 | ₹3.26 M | Open |
How Many Employees Work at Cytocare Technologies?
Unlock and access historical data on people associated with Cytocare Technologies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cytocare Technologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cytocare Technologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
